Humacyte, Inc. (HUMA) Current Ratio
- Current ratio · latest quarter: Value 6.21×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.21× | Current assets / current liabilities. $92.79M ÷ $14.95M ≈ 6.21× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 92.79M USD | Assets, Current |
| Current obligations | 14.95M USD | Liabilities, Current |
| Cash and equivalents | 79.90M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 330.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 6.99M USD | Inventory, Net |
| Payables | 4.16M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $92.79M | $14.95M | $79.90M | (m) | $330.00K | $6.99M | $4.16M | (m) | 6.21× |
| 2026-03-31 | $63.60M | $16.19M | $48.54M | (m) | $434.00K | $9.92M | $5.08M | (m) | 3.93× |
| 2025-12-31 | $67.80M | $18.37M | $50.50M | (m) | $441.00K | $13.59M | $5.40M | (m) | 3.69× |
| 2025-09-30 | $41.35M | $25.58M | $19.49M | (m) | $1.08M | $18.42M | $9.57M | (m) | 1.62× |
| 2025-06-30 | $51.73M | $21.09M | $38.03M | (m) | $394.00K | $11.07M | $6.63M | (m) | 2.45× |
| 2025-03-31 | $73.70M | $20.03M | $62.85M | (m) | $488.00K | $8.02M | $5.57M | (m) | 3.68× |
| 2024-12-31 | $47.86M | $19.95M | $44.94M | (m) | $0.00 | $0.00 | $4.49M | (m) | 2.40× |
| 2024-09-30 | $23.00M | $20.94M | $20.57M | (m) | (m) | (m) | $6.90M | (m) | 1.10× |
| 2024-06-30 | $96.11M | $17.76M | $93.56M | (m) | (m) | (m) | $6.00M | (m) | 5.41× |
| 2024-03-31 | $117.93M | $14.09M | $115.50M | (m) | (m) | (m) | $3.45M | (m) | 8.37× |
| 2023-12-31 | $83.28M | $18.44M | $80.45M | (m) | (m) | (m) | $6.49M | (m) | 4.52× |
| 2023-09-30 | $102.85M | $15.14M | $99.99M | (m) | $0.00 | (m) | $3.02M | (m) | 6.79× |
| 2023-06-30 | $120.56M | $11.39M | $114.60M | (m) | $0.00 | (m) | $2.36M | (m) | 10.59× |
| 2023-03-31 | $133.85M | $23.60M | $129.57M | (m) | $0.00 | (m) | $1.95M | (m) | 5.67× |
| 2022-12-31 | $154.21M | $19.58M | $149.77M | (m) | $31.00K | (m) | $1.59M | (m) | 7.88× |
| 2022-09-30 | $174.61M | $17.91M | $163.73M | (m) | $31.00K | (m) | $3.25M | (m) | 9.75× |
| 2022-06-30 | $193.03M | $11.06M | $181.03M | (m) | $1.30M | (m) | $2.54M | (m) | 17.46× |
| 2022-03-31 | $209.29M | $10.76M | $198.22M | (m) | $233.00K | (m) | $3.04M | (m) | 19.45× |
| 2021-12-31 | $229.34M | $11.05M | $217.50M | (m) | $176.00K | (m) | $2.09M | (m) | 20.75× |
| 2021-09-30 | $244.18M | $21.25M | $240.45M | (m) | $240.00K | (m) | $5.83M | (m) | 11.49× |
| 2021-06-30 | $462.78K | $219.84K | $383.40K | (m) | (m) | (m) | $6.36K | (m) | 2.11× |
| 2021-03-31 | $637.64K | $135.65K | $513.06K | (m) | (m) | (m) | $5.00K | (m) | 4.70× |
| 2020-12-31 | $41.45M | $11.23M | $39.93M | (m) | $113.00K | (m) | $2.27M | (m) | 3.69× |
| 2020-09-30 | $1.35M | $120.47K | $1.32M | (m) | (m) | (m) | $27.06K | (m) | 11.18× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |